REMEDY : BNSSG referral pathways & Joint Formulary

Home > Formulary : Adult > Chapters > 1. Gastro-Intestinal System >

BNSSG Adult Joint Formulary

1.8 Obesity

Last edited: 26-01-2024

First line drugs Second line drugs Specialist drugs Secondary care drugs


Lipase Inhibitors

Orlistat (TLS Green) - primary care initiation only


GLP-1 (Glucagon- Like Peptide 1) Receptor

A NPSA alert has been issued  'Shortage of GLP-1 receptor agonists (GLP-1 RA)' advising that there are very limited, intermittent supplies of all GLP-1 RAs. Supply is not expected to return to normal until at least mid-2024. Please refer to the actions to be completed in the NPSA alert.

Liraglutide (Saxenda®) (TLS Red)

  • NICE TA664 Liraglutide for managing overweight and obesity

Semaglutide (Wegovy®) (TLS Red)

  • NICE TA875 Semaglutide for managing overweight and obesity


Contact Us

Got a question or comment about the Joint Formulary? 

Please use the email address below to contact us and we will endeavour to respond within 2 working days.